In 2016, CRI supported laboratory, translational, and clinical research in 13 countries, including 20 U.S. states.

From Our Leadership

Just five years ago, when talking about outcomes of patients treated for late-stage cancers, “cure” wasn’t a word our scientists were likely to use. Today, the outlook is significantly better, with cancer immunotherapy now offering patients a real chance—not only at surviving longer, but also at living better without the debilitating side effects often seen with conventional cancer treatments. At last, we can say that cures for cancer are within reach.

This didn’t happen overnight. It has taken a long view of progress and decades of research to build a foundation for the new therapies available to patients today. Lifesaving drugs like the FDA-approved immunotherapies Yervoy®, Opdivo®, Keytruda®, Imlygic®, and others are built upon fundamental knowledge of the immune system, its components, and how they function. This knowledge was hard won by a global community of immunologists and tumor immunologists, many of whom have relied on funding from the Cancer Research Institute to carry out their important work.

In fiscal year 2016 (July 1, 2015, to June 30, 2016), we continued to push the limits of human knowledge and open the way for new and more effective immunotherapies by awarding over $23.6 million to support highly promising laboratory, translational, and clinical research around the world.

We also recognize the need to help patients and their caregivers navigate what can be an overwhelming introduction to this new treatment approach. In 2016, we invested in educational programming to provide them trusted information and connect them to immunotherapy clinical trials. And as part of our Cancer Immunotherapy Month awareness campaign in June, we introduced more than 3.8 million people worldwide to the exciting progress being made today thanks to immunotherapy breakthroughs.

We are proud that we are able to make these important contributions to the global cancer research and patient communities while also maintaining our high ratings with charity watchdogs, including four out of four stars from Charity Navigator and membership within the Better Business Bureau’s Wise Giving Alliance, among others.

None of this lifesaving work would be possible without the generous support of our donors like you. On whom we rely. We extend our heartfelt thanks on behalf of the thousands of CRI-funded scientists and the millions of cancer patients worldwide who may benefit from your support.
Powering Innovation

The CRI Irvington Postdoctoral Fellowship Program provides training and financial support to young scientists working in the laboratories of leading cancer immunologists around the world. Fellowships provide up to $175,500 over three years.

Our postdoctoral fellows are the best and the brightest, bringing new energy to tackle the most pressing areas of research today. Their investigations deepen our knowledge of the immune system and lay the foundation for new immunotherapies for all types of cancer. In the past year:

Leticia Corrales, Ph.D., of the University of Chicago, in Chicago, IL, engineered a small molecule of PD-1 and demonstrated its effectiveness in treating both small and large colorectal cancer tumors.

Rony Dahan, Ph.D., of The Rockefeller University, in New York, NY, demonstrated how the tail region of checkpoint inhibitor antibodies can affect immunotherapy responses, providing key insights to support the development of next-generation checkpoint inhibitors.

P.C. Dave P. Dingal, Ph.D., of Stanford University School of Medicine, in Stanford, CA, created a system that allows researchers to manipulate the activity of genes to better characterize and understand the immune system’s dynamics.

Bengt Martin Gustavsson, Ph.D., of the University of California, San Diego, in San Diego, CA, developed new ways to design and analyze the binding affinity of a key immune molecule, called a chemokine, to enable more effective drug design.

Jiajui Hu, Ph.D., of the Boston Children’s Hospital, in Boston, MA, discovered how enzymes called RAGs can cause improper DNA rearrangements that have been implicated in B cell lymphoma, a deadly type of blood cancer.

Helene M. Salmon, Ph.D., of the Icahn School of Medicine at Mount Sinai, in New York, NY, revealed how dendritic cells coordinate anti-melanoma responses, and developed an approach to enhance their anti-cancer activity in combination with checkpoint inhibitors.

Estela P. Jacinto, Ph.D.
Associate Professor,
Rutgers University
CRI Irvington Postdoctoral Fellow, 1999-2002

"CRI is at the forefront of supporting innovative and highly promising research. As a postdoctoral fellow, I relied on CRI’s funding of my basic research, considered at the time by some as lacking cancer relevance. Yet, it turned out that it’s now one of the main focuses in cancer therapy development."

Margaret K. Callahan, M.D., Ph.D., recently the Lloyd J. Old Memorial Fellow at Memorial Sloan Kettering Cancer Center in New York, NY, demonstrated in a phase III clinical trial for metastatic melanoma that combining the immunotherapies ipilimumab (Yervoy®) and nivolumab (Opdivo®) resulted in significantly longer progression-free survival than ipilimumab alone. In fiscal year 2016, the combination received FDA approval as a first-line treatment for melanoma.

For a complete list of all 102 postdoctoral fellows active in FY2016, go to page 18
Bridging Basic and Clinical Science

The Clinic and Laboratory Integration Program (CLIP) supports scientists conducting translational research aimed at improving the effectiveness of immunotherapies. CLIP grants provide up to $200,000 over two years.

Recent clinical outcomes from immunotherapy trials have generated new scientific questions and high demand for research funding. CRI established CLIP to facilitate better dialogue between the laboratory and clinic. By channeling support into this “translational” area, CRI supports an iterative research loop that can lead to new and more effective immunotherapies.

Juan R. Cubillos-Ruiz, Ph.D.
Assistant Professor of Microbiology and Immunology, Well Cornell Medicine, New York, NY
While immune cells can slow and even halt ovarian cancer progression, immunosuppressive factors in the tumor environment can reduce their potency. Cubillos-Ruiz is investigating a newly recognized fatty acid, or lipid, that enables ovarian tumors to evade immune attack. He will study whether blocking the lipid’s receptor can enhance anti-tumor immune responses. Promising results could lead to therapeutic drug combinations that improve survival in ovarian cancer patients.

Amanda Lund, Ph.D.
Assistant Professor of Cell & Developmental Biology; Molecular Microbiology & Immunology; and Dermatology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
Lund is working to improve our understanding of how lymph-transporting vessels affect our immune system’s ability to carry out anti-tumor immune responses against melanoma. Abnormal lymphatic growth is associated with cancer, and Lund hypothesizes that tumors may be “hijacking” these vessels to escape the immune system. Lund’s work may enhance immunotherapy approaches that target these vessels and improve survival in melanoma patients.

Power of Biomarkers

Haidong Dong, M.D., Ph.D., a 2015-2017 CLIP investigator and associate professor of immunology at the Mayo Clinic in Rochester, MN, discovered that the Bim biomarker on T cells can predict how well patients might potentially respond to immunotherapy, and provides a way to observe ongoing anti-cancer immune responses. If validated, this biomarker will help doctors to monitor an immunotherapy’s effectiveness in patients.

IMPACT

For a complete list of all CLIP investigators active in FY2016, go to page 22
The Anna-Maria Kellen Clinical Accelerator is CRI’s venture philanthropy program designed to help spur the creation of next-generation combination cancer immunotherapies through partnerships with academia and industry.

CRI’s clinical program fosters collaboration across top academic research groups, biopharma companies, and nonprofit partners to design, conduct, manage, and fund scientifically-driven clinical trials with high potential for success. These trials make available to patients new and promising treatment combinations that they otherwise could not access.

Prioritized studies are launched with a comprehensive set of nonprofit resources and a unique IP model that facilitates access to top drugs from different companies. Clinical Accelerator currently has more than 15 significant industry and nonprofit partners.

The model is powered by a nonprofit venture capital fund, which enables it to achieve significant leverage via co-investments and is structured to become self-sustaining over time via returns on investment back to the charity as supported drugs demonstrate their effectiveness. The backbone of the program, the CVC Clinical Trials Network, is powered by more than 80 clinician scientists around the world and is managed jointly by CRI and its partner, Ludwig Cancer Research.

It’s a win-win-win model: cancer patients gain access to promising new treatment options; scientists gain extraordinary clinical research and publication opportunities; and company partners gain valuable investment of nonprofit resources and expertise into their drugs.

CRI’s Clinical Accelerator allows me to provide cutting-edge immunotherapy combinations to patients with glioblastoma, a type of brain cancer that is difficult to treat and which may be a promising target for immunotherapy.

David A. Reardon, M.D.
Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute
CVC Clinical Trials Network Member, 2012-present

To date, Clinical Accelerator investments have supported 10 phase I and II cancer immunotherapy clinical trials. These trials are bringing novel immunotherapy combinations into the clinic and will ultimately treat over 800 patients spanning 20 types of cancer, including very hard-to-treat cancers like glioblastoma, a type of brain cancer, triple-negative breast cancer, and colorectal cancer.
Harnessing Industry Expertise

The Cancer Immunotherapy Consortium (CIC) is a think tank of industry leaders from the cancer immunotherapy field who seek solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit.

The CIC was founded in 2002 as an international membership association of pharmaceutical and biotechnology companies and academic institutions with a common interest in immunotherapy research and development, with the ultimate goal of making cancer immunotherapies part of the standard-of-care in oncology.

With the 2011 FDA approval of ipilimumab (Yervoy®), an immune checkpoint inhibitor drug, the first milestone toward this goal was achieved. Given the substantial increase in development activity and clinical success of other immunotherapy agents that followed, and in an effort to continue to provide maximum value to the rapidly evolving field, the direction of the CIC was re-set to become a “think tank” that would convene and tackle topics of importance to the continued development of cancer immunotherapies.

The CIC now acts as a neutral platform whereby industry representatives work together to discuss important issues and collectively facilitate solutions to challenges in late-stage drug development, with the goal of accelerating patient benefit. Outcomes will be available to all stakeholders in the field through publishing of CIC proceedings. Current topics under review include application of immune-related Response Criteria (irRC) across clinical studies in multiple tumor types, and second-generation biomarkers.

Finding a Common Language

In 2016, CIC Steering Committee members identified important next steps toward the development of shared definitions of patient outcomes that can be used across different company-sponsored drug trials when describing tumor progression within the context of immunotherapy treatment. The development of common methods for assessing and reporting patient outcomes may allow for improved trial design and generation of data that facilitates FDA review of new immunotherapies.

Daniel S. Chen, M.D., Ph.D.
Vice President, Global Head of Cancer Immunotherapy Development,
Genentech/Roche
Co-Chairman, CIC Steering Committee

Through the CIC, companies with immunotherapies in development can work together toward the same goal, finding solutions that will help the entire industry and, ultimately, cancer patients.
The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference is a scientific meeting devoted to exploring the latest research in cancer immunology and immunotherapy. It attracts clinicians, scientists, government regulators, drug developers, and patient groups.

With the explosion of interest in cancer immunotherapy and the proliferation of scientific meetings in the field, the Cancer Research Institute, along with the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR), decided to join forces to sponsor the International Cancer Immunotherapy Conference devoted to exploring the latest research in cancer immunology and immunotherapy.

The theme of the inaugural September 2015 meeting, held in New York City, was “Translating Science Into Survival,” and featured over 60 presentations from leaders in immunology and cancer immunotherapy. Emerging themes included new genetic targets for personalized immunotherapies, the relationship between the microbiome and cancer, and new targets for checkpoint blockade, chimeric antigen receptor (CAR) treatment, and vaccine therapy. There was also a snapshot of the regulatory landscape for cell and gene therapy, biomarkers and their function in patient selection, imaging and its role in targeting the anti-tumor response, and immunotherapy trial designs.

The September 2015 conference attracted more than 1,400 participants from 38 countries across Asia, Australia, Europe, North America, and South America. More than 375 scientists presented their research at the meeting’s poster sessions, and CRI postdoctoral fellows and other meeting participants took advantage of the many networking opportunities. Due to high demand, the organizers hosted a second conference in 2016 in New York City, and a third will take place in Mainz/Frankfurt, Germany in 2017.
Cancer immunotherapy is a fast-moving field, and keeping up can be challenging. We provide educational programs and awareness initiatives designed to reach people who are unaware of immunotherapy’s promise and connect them to resources and communities that can help them on their treatment journeys.

Preferred Destination for Trusted Information
More than 1 million website visitors per year rely on free information we provide on immunotherapy research and treatment for more than 20 different types of cancer.

Immunotherapy Clinical Trial Finder
This fully supported service, the only one of its kind devoted exclusively to cancer immunotherapy trials, has helped more than 4,500 people take the first step in exploring their immunotherapy options.

Cancer Immunotherapy Month
This series of educational, social, and athletic events in June promotes awareness of cancer immunotherapy and raises funds to support lifesaving research. Our most recent June activities featured:
- Immunotherapy Patient Stories: Inspiring videos of patients sharing their experiences with cancer immunotherapy
- Cancer Immunotherapy and You: Free webinars for patients and caregivers featuring immunotherapy experts and interactive Q&A
- Immunotherapy and Chemotherapy: What's the Difference?: Animated video explaining how these treatments work as well as their potential benefits and possible side effects
- Ask a Scientist: Short videos inviting immunotherapy experts to address the most frequently asked questions from patients
- What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2016: An expert panel discussing new developments in cancer immunotherapy research and treatment from the world’s largest cancer conference

Social Media and Offline Special Events
- #WhiteOutCancer Day: This global social media event invited people to show their support for cancer immunotherapy research by wearing white and posting a “selfie” to Facebook, Twitter, and Instagram or by uploading a personalized message with a photo to our website at whiteoutcancer.com
- Answer to Cancer Cycling Event: On June 25, 2016, more than 220 cyclists rode 100, 50, or 25 miles through historic West Point and the surrounding Lower Hudson Valley in New York during this inaugural fund- and awareness-raising event sponsored by Bristol-Myers Squibb
- Corporate Events: Participating companies around the world engaged thousands of their employees in day-long awareness, education, and fundraising activities designed to highlight progress in cancer treatment and promote company commitment to social responsibility and employee health

Thank you to all of our generous partners and supporters
Abbvie; Agensia; Basin Holdings; Bristol-Myers Squibb Company; Brooklyn Brewery; Celldex Therapeutics, Inc.; Clayton, Dubilier & Rice, LLC; Debevoise & Plimpton LLP; Finish Line Physical Therapy; Genentech; Hincapie Sportswear; Holowesko Citadel; Horseneck Wines & Liquors; Hudson Valley Harvest; Inovio Pharmaceuticals; LabAnswer and its employees; Merck, known as MSD outside the U.S. and Canada; Mitsubishi UFJ Securities; Nestle Waters North America; NewLink Genetics; PPD; Regeneron Pharmaceuticals; Reynolds Cycling LLC; The Sweat Life; Tailwind Endurance; and USA Cycling

The more people who enter trials, the more people who are educated, the more power we as patients have.

Stephen E. colorectal cancer survivor

To learn more, visit cancerresearch.org/june
Recognizing Excellence

Each year, the Cancer Research Institute honors individuals and organizations that have made important contributions to the field of cancer immunotherapy.

The William B. Coley Award for Distinguished Research in Basic Immunology
Alexander Y. Rudensky, Ph.D., Memorial Sloan Kettering Cancer Center, Howard Hughes Medical Institute, New York, NY, for his contributions to our understanding of regulatory T cells, which play an important role in restraining immune responses and inflammation

The William B. Coley Award for Distinguished Research in Tumor Immunology
Glenn Dranoff, M.D., Novartis Institutes for BioMedical Research, Cambridge, MA, for his many contributions to the development of cancer immunotherapies, including the design and testing of the therapeutic cancer vaccine GVAX

The Frederick W. Alt Award for New Discoveries in Immunology
Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY, for her pioneering work on dendritic cells, which are key antigen-presenting cells that play an important role in starting the immune response

AACR-CRI Lloyd J. Old Award in Cancer Immunotherapy
Ronald Levy, M.D., Stanford University School of Medicine, Stanford, CA, for his work on developing rituximab (Rituxan®), the first monoclonal antibody to be approved by the FDA, in 1997

The Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research
Kenneth C. Frazier, Chairman and CEO, Merck & Co., for advancing immuno-oncology research and drug development

Lauren S. Veronis, Trustee, Cancer Research Institute, and Former President, Irvington Institute for Immunological Research, for her many years of devotion to advancing immunological research through her leadership and fundraising efforts

I’ve always thought immunotherapy had an enormous potential to create an ongoing engine of opposition to cancers.

Bill Clinton
42nd President of the United States
Keynote Speaker, CRI 39th Annual Awards Dinner

To view all CRI award recipients, visit cancerresearch.org/honorees
In fiscal year 2016 (July 1, 2015, to June 30, 2016), the Cancer Research Institute awarded more than $23.6 million for cancer immunology research and cancer immunotherapy clinical development.

*Denotes grants newly awarded in fiscal year 2016. All others are active grants awarded in previous years.
Lomonosov Moscow State University, Moscow, Russia
Sergei A. Nekudais, Ph.D., D.Sc.
Lloyd J. Old Advanced Training Program in Immunology and Oncoimmunology

CRI IRVINGTON POSTDOCTORAL FELLOWSHIP PROGRAM
Three-year awards that further the career development and advanced laboratory research of promising postdoctoral fellows working under the mentorship of world-class immunologists and tumor immunologists.

Boston Children’s Hospital, Boston, MA
Zhaqing Ba, Ph.D.*
Mechanisms that mediate intralocus and inter-locus regulation of V(D)J recombination at immunoglobulin light chain loci

Samuel and Ruth Engelberg Fellow

Bradley Wayne Blaser, M.D., Ph.D.
Immunologic regulation of hematopoietic stem cell engraftment

University of California, Berkeley, Philadelphia, PA
Thomas Chia Ting Fung
Role of innate lymphoid cell-controlled intestinal barrier function in hepatocellular carcinoma

University of California, Berkeley, CA
Thornton William Thompson
The role of oncogene-induced senescence in promoting anti-tumor immune responses

F.M. Kirby Fellow

PREDOCTORAL EMPHASIS PATHWAYS IN TUMOR IMMUNOLOGY
Four-year awards to universities to support establishment and maintenance of tumor immunology training courses for graduate students.

Johns Hopkins University School of Medicine, Baltimore, MD
Director: Charles G. Drake, MD, Ph.D.

University of Colorado, Denver, CO
Directors: John Kappler, Ph.D., and Philippa Marrack, Ph.D.

University of Colorado, Boulder, CO

Ling Zhang, Ph.D.*
Structural studies of NAIP/NLRC4 inflammasomes in immunity and cancer

Broad Institute of MIT and Harvard, Cambridge, MA
Le Cong, Ph.D.*
Dissection of cellular states and transcriptional networks regulating innate immunity during tumorogenesis

California Institute of Technology, Pasadena, CA
Andrew I. Flyak, Ph.D.*
The structural basis of hepatitis C virus neutralization by broadly neutralizing human antibodies

Children’s Hospital of Philadelphia, Philadelphia, PA
Nathan Roy, Ph.D.*
Modulation of T cell trafficking by Crk adapter proteins

Columbia University Medical Center, New York, NY
Yenkel Grinberg-Bleyer, Ph.D.
Testing the role of NFκB in tumor immunity through its effect on regulatory T cells

 disciplined by defining the role of long non-coding RNAs in CD8+ T cell differentiation

Emory University, Atlanta, GA
William H. Hudson, Ph.D.*
Deciphering the role of long non-coding RNAs in CD8+ T cell differentiation

Harvard Medical School, Boston, MA
Carmen Gerlach, Ph.D.
Differentiation, function, and dynamic behavior of transitional memory cells: A novel subset of CD8+ memory T cells

Alexandra M. Greer, Ph.D.*
The role of ubiquitin-1 in B cell receptor-driven lymphoma proliferation

Jason Hudak, Ph.D.
Understanding microbial sensing in colorectal cancer using bioorthogonal chemistry

Liu Jin, Ph.D.*
Differentiation and accumulation of adipose-tissue regulatory T cells: Important players in the immunological control of metabolism and obesity-associated cancer

Children’s Hospital of Philadelphia, Philadelphia, PA
Nathan Roy, Ph.D.*
Modulation of T cell trafficking by Crk adapter proteins

Columbia University Medical Center, New York, NY
Yenkel Grinberg-Bleyer, Ph.D.
Testing the role of NFκB in tumor immunity through its effect on regulatory T cells

Dana-Farber Cancer Institute, Boston, MA
Adam N.R. Cartwright, Ph.D.*
Systematic discovery of combination immunotherapy targets

ICahn School of Medicine at Mount Sinai, New York, NY
Helenem M. Salmon, Ph.D.
Contribute-year of the cutaneous myeloid network to melanoma response to therapy

Robertson Foundation Fellow

Institut Curie, Paris, France
Yvonne K. Mburu, Ph.D.
Mucosal-associated invariant T cells in anti-tumor therapy

Lloyd J. Old Memorial Fellow

La Jolla Institute for Allergy and Immunology, La Jolla, CA
Chuan-Wang J. Liao, Ph.D.
Role of long non-coding RNAs in the development of T cell leukemia

Christophe Pedros, Ph.D.*
Control of regulatory T cell function by protein kinase C-beta (PKCβ): A novel target for cancer immunotherapy

Massachusetts Institute of Technology, Cambridge, MA
Alexandra Boussoummier, Ph.D.
Characterizing the role of macrophages in breast cancer cell extravasation and recognition in organ-specific 3D microfluidic models

Maria P. Frushicheva, Ph.D.
ZAP-70 and Syk regulation in B cell chronic lymphocytic leukemia

Fella Tamzalit, Ph.D.
The role of the centrosome in cytotoxic T cell function

Lloyd J. Old Memorial Fellow

Exploring colonization resistance against Legionia monocytogenes in cancer patients

Pu Gao, Ph.D.
Structural and functional studies of cytotoxic DNA sensing pathway

Samantha and Ruth Engelberg Fellow

Jing-Ping Hsin, Ph.D.
The effects of cellular context on mRNAs mediated regulation of gene expression

Young Philanthropists Council Fellow

Wei Hu, Ph.D.
Tissue repair function of regulatory T cells during infection and cancer progression

Fella Tamzalit, Ph.D.
The role of the centrosome in cytotoxic T cell function

Lloyd J. Old Memorial Fellow

Helene M. Salmon, Ph.D.
Mucosal-associated invariant T cells in anti-tumor therapy

Robertson Foundation Fellow

Jesse Green, Ph.D.
Interactions of regulatory T cells with the tumor endothelium and effects on the tumor microenvironment

Samuel and Ruth Engelberg Fellow

Heng Ru, Ph.D.
Structural and biochemical studies of the antigen receptor gene recombination machinery

Simone Becattini, Ph.D.*

Cancer Research Institute 2016 Annual Report

Fella Tamzalit, Ph.D.
Haidong Tang, Ph.D.
Tumor-specific LIGHT targeting for cancer immunotherapy

University of Washington School of Medicine, Seattle, WA
Jonathan M. Clingan, Ph.D.
Integration of transcriptional and translational control of the antiviral response

Elizabeth Gray, Ph.D.
Functional analysis of the interferon stimulatory DNA pathway

Marc Joseph Lajoie, Ph.D.*
Protein nanoparticles to elicit defined T cell response against cancer cells

University of Wisconsin-Madison, Madison, WI
Davidency R. Powell, Ph.D.
The role of neutrophils and CXCL8-CXCR2 signaling in glioblastoma cell invasion

Vanderbilt University, Nashville, TN
Katy Beckemann, M.D., Ph.D.*
Metabolic barriers to T cell function and immunotherapy in renal cell carcinoma

Merck Fellow

Washington University School of Medicine, St. Louis, MO
Jennifer K. Bando, Ph.D.
Immune modulation of dormant skin tumor development and persistence

Matthew M. Gubin, Ph.D.
Using genomics to identify targets of checkpoint blockade cancer treatment and to identify optimal target antigens for vaccination

Whitehead Institute for Biomedical Research, Cambridge, MA
Yang Eric Guo, Ph.D.
Biogenesis and regulatory functions of super-enhancer RNAs in cancer cells of the immune system

Giulia Pasqual, Ph.D.
In vivo tracking of B cell-T cell interactions in the germinal center

Kehui Xiang, Ph.D.*
Investigate the importance and mechanism of poly(A) tail length-mediated translational control in different immune cells

Yale University School of Medicine, New Haven, CT
Najla Arshad, Ph.D.
The effect of tumor-associated mutant calreticulin on antigen presentation and tumorigenesis

Will H. Bialis, Ph.D.
Identification and characterization of immune escape mechanisms in leukemia

Guoliang Cui, M.D., Ph.D.
The influence of nutrient availability in the tumor microenvironment on CD8+ T cell survival and function

Ruth A. Franklin, Ph.D.
The role of macrophages in tissue homeostasis and tumor progression

Dr. Keith Landesman Memorial Fellow

Noah Wolcott Palm, Ph.D.
Role of helminth infections and the commensal microbiota in intestinal inflammation

Deuprob Sengupta, Ph.D.
Membrane trafficking events regulating cross presentation

INVESTIGATOR AWARDS
Four-year bridging grants to assistant professors undertaking their first independent investigations in basic and tumor immunology, designed to provide flexibility and stability while they establish their laboratories.

Liang Zhou, M.D., Ph.D.
Northwestern University, Chicago, IL
Molecular mechanisms of action of Ahr in T cell differentiation and function

CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP)
Two-year grants that provide catalytic support for translational laboratory studies designed to answer new scientific questions that arise in the clinic, with special focus on improving immunotherapy for cancer patients.

Austin Health/Ludwig Cancer Research, Melbourne, Australia
Jonathan S. Cobon, Ph.D., FRACP
Evaluation of ROPN and SPANX as targets for antigen-specific immunotherapy

Wade F.B. Thompson Investigator

Brigham and Women’s Hospital/ Harvard Medical School, Boston, MA
Niroshanha Anandasabapathy, M.D., Ph.D.*
Actioning a newly-defined target of peripheral tumor-immune surveillance in dendritic cells

Broad Institute of MIT and Harvard, Cambridge, MA
Nir Hacohen, Ph.D.
Unbiased single cell analysis of the lung tumor microenvironment to understand failure modes of checkpoint blockade inhibitors

Wade F.B. Thompson Investigator

Cancer Research Center of Toulouse Purpan, Toulouse, France
Roland S. Liblau, M.D., Ph.D.
EVER proteins: Immune control of skin infection by beta-human papillomaviruses and skin cancer

Columbia University Medical Center, New York, NY
David M. Owens, Ph.D.
Therapeutic targeting of intrinsic T cell suppression during anti-tumor immunity

Dana-Farber Cancer Institute, Boston, MA
Michael Goldberg, Ph.D.
Use of CRISPR/Cas9 platform to improve function of cytotoxic T lymphocytes against melanoma

Fondazione Centro San Raffaele, Milan, Italy
Matteo Bellone, M.D.
Therapeutic targeting of BRAF in solid tumors

Icahn School of Medicine at Mount Sinai, New York, NY
Nina Bharadwaj, M.D., Ph.D.*
Analysis of immune responses induced by in situ, autologous therapeutic vaccination against solid cancers with intratumoral Poly-ICLC (Hiltonol®)

Joshua Brody, M.D.
Understanding a novel in situ lymphoma vaccine: Neoadtigen discovery with whole exome sequencing and neoantigen-reactive T cell checkpoint molecule profiling with CyTOF

La Jolla Institute for Allergy and Immunology, La Jolla, CA
Stephen P. Schoenberger, Ph.D.
Exome-guided neoantigen discovery and validation in head and neck squamous cell carcinoma

Leiden University Medical Center, Leiden, The Netherlands
Ferry A. Ossendorp, Ph.D.
Novel vaccine nanofomulations for clinical mutanome-based cancer immunotherapy

Massachusetts General Hospital, Boston, MA
Rakesh K. Jain, Ph.D.
Targeting the CXCR3 chemokine receptor during anti-PD-1 therapy

Medical University of South Carolina, Charleston, SC
Mark P. Rubinstein, Ph.D.*
Generating human tumor-reactive T cells with high levels of IL-2Rα for adoptive T cell therapy

Memorial Sloan Kettering Cancer Center, New York, NY
Alexander Y. Rudensky, Ph.D.
Immuno-regulatory correlates of a phase I/II study of mogamulizumab in subjects with advanced and/or metastatic solid tumors

Genentech Investigator

Northwestern University, Chicago, IL
Derek A. Wainwright, Ph.D.*
IDO3 in glioblastoma: Translating work from mouse to man

Wade F.B. Thompson Investigator

NYU Langone Medical Center, New York, NY
John Carucci, M.D., Ph.D.
Targeting the immune system to treat aggressive squamous cell carcinoma

Oregon Health & Science University, Portland, OR
Amanda Lund, Ph.D.
FASL–expressing lymphatic vessels in melanoma

Osaka University, Osaka, Japan
Hiroyoshi Nishikawa, M.D., Ph.D.
Novel cancer immunotherapy targeting regulatory T cells by anti-CCR4 monoclonal antibodies

Ottawa Hospital Research Institute, Ottawa, Canada
John C. Bell, Ph.D.*
Bioengineering an oncolytic vaccinia virus to augment the anti-tumor immune response in human cancers

QIMR Berghofer Medical Research Institute, Brisbane, Australia
Mark J. Smyth, Ph.D., FAHMS
The preclinical validation of CD46 as a checkpoint target for cancer immunotherapy

Wade F.B. Thompson Investigator

CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
Saint Louis University School of Medicine, St. Louis, MO
Ryan M. Teague, Ph.D.
Defining the mechanisms of human T cell rescue by checkpoint blockade immunotherapy

Stanford University School of Medicine, Stanford, CA
Dean W. Felsher, M.D., Ph.D.
Oncogene addiction and immune activation

The University of Chicago, Chicago, IL
Thomas F. Gajewski, M.D., Ph.D.
Characterization and prevention of "stunning," a cytotoxic T lymphocyte inactivating program that impairs adoptive cell therapy for improving anti-tumor immune responses

University of Minnesota, Minneapolis, MN
Bruce R. Blazar, M.D.
Lymphoma recovery after cancer therapy for improving anti-tumor immune responses

University of Oxford, Oxford, United Kingdom
Paul Kemsley, M.D., Ph.D.
Licensing human mucosal-associated invariant T cells to kill hepatocellular carcinomas

University of Southern California, Los Angeles, CA
W. Martin Kast, Ph.D.
Anti-CTLA-4 immune modulation following chemoradiation in cervical cancer patients

The University of Texas MD Anderson Cancer Center, Houston, TX
Michael A. Curran, Ph.D.*
Hypoxia drives tumor immune suppression and immunotherapy resistance

University of Virginia Health System, Charlottesville, VA
Craig L. Slingluff Jr., M.D.
Retention integrins: Induction and function on cancer-reactive T lymphocytes

UCLA Medical Center, Los Angeles, CA
Roger S. Lo, M.D., Ph.D.
Determinants of responses to anti-PD-1/PD-L1 therapy and its combination with BRAF/MEK co-targeting in melanoma

Wade F.B. Thompson Investigator

University Autónoma de Madrid, Madrid, Spain
Bruno Sainz Jr., Ph.D.
Role of the innate immune system in promoting cancer stem cells

University Health Network, Toronto, Canada
Tak W. Mak, Ph.D., D.Sc., F.R.S.C.*
Evaluating the role of Toso-mediated inflammation in anti-tumor responses

University Hospital of Lausanne, Lausanne, Switzerland
Daniel E. Speiser, M.D.
Identification and validation of new targets for cancer immunotherapy in "exhausted" anti-cancer CD8+ T cells from mice and humans

University of California, San Francisco, CA
Markus Muschen, M.D., Ph.D.*
Targeted hyperactivation of B cell receptor signaling to amplify therapeutic responses to CART19 treatment

University of Minnesota School of Medicine, St. Louis, MO
Gavin P. Dunn, M.D., Ph.D.*
Monitoring the immunomodulator immune response in glioblastoma patients treated with a personalized necroptosis vaccine

Well Cornelius Medicine, New York, NY
Juan R. Cubillos-Ruiz, Ph.D.*
Targeting LPA sensors in the tumor microenvironment to enhance ovarian cancer immunotherapies

Wade F.B. Thompson Investigator

Yale School of Medicine, New Haven, CT
Susan M. Kaech, Ph.D.
Enhancing immunotherapy-based cancer treatments through CD40-dependent immunomodulation of the tumor microenvironment

Wade F.B. Thompson Investigator

COORDINATED CANCER INITIATIVES

Funding for research in specified cancer areas deemed able to provide clinically relevant insights and discoveries with the potential to accelerate development of cancer immunotherapies.

Centre de Lutte Contre Le Cancer Nantes-Atlantique, Nantes-Saint Herblain, France
Daniela Valmori, Ph.D.
Vaccination strategies for the treatment of epithelial ovarian cancer

Icahn School of Medicine at Mount Sinai, New York, NY
Hearm Jay Cho, M.D., Ph.D.
Vaccine immunotherapy program in multiple myeloma

Cancer Research Institute 2016 Annual Report
Team Lead: Lei Zheng, M.D., Ph.D., Investigators: Elizabeth Jaffee, M.D., Eric Lutz, Ph.D., Todd Armstrong, Ph.D., Johns Hopkins University School of Medicine, Baltimore, MD Tipping the balance in the tumor microenvironment as a next generation platform for pancreatic cancer immunotherapy

CLINICAL TRIALS FUNDED

A first-in-human single ascending dose study of TRP538 in subjects with unresectable stage III or stage IV malignant melanoma or other solid tumor malignancies

- Henry Koon, M.D., University Hospitals, Cleveland, OH
- Dale Shepard, M.D., Ph.D., Cleveland Clinic, Cleveland, OH
- Jedd D. Wolochok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY

An open label, phase I study of a neoantigen vaccine (TESLA-001), with a checkpoint inhibitor, in combination with tremelimumab in subjects with advanced solid tumors

- Kunle Odunsi, M.D., Ph.D., Anna-Maria Kielien Clinical Investigator, Roswell Park Cancer Institute, Buffalo, NY
- Patrick Ott, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA
- Jedd D. Wolochok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY

A phase I/II study to evaluate the safety and tolerability of tremelimumab and durvalumab, administered with high dose chemotherapy and autologous stem cell transplant

- Hearn Jay Cho, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY
- Alexander M. Lesokhin, M.D., Memorial Sloan Kettering Cancer Center, New York, NY

A phase I/II study to evaluate the safety of tremelimumab and durvalumab, in combination with tremelimumab in subjects with advanced solid tumors

- Kunle Odunsi, M.D., Ph.D., Anna-Maria Kielien Clinical Investigator, Roswell Park Cancer Institute, Buffalo, NY
- Patrick Ott, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA
- Jedd D. Wolochok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY

A phase I/II dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies

- Dimitry Zamarin, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY

A study of ALK inhibitor, ensartinib, and anti-PD-L1 durvalumab, in subjects with ALK-rearranged non-small cell lung cancer

A phase I/II study of combination immunotherapy and mRNA vaccine in subjects with non-small-cell lung cancer (NSCLC)

- Leena Gandhi, M.D., Ph.D., NYU Langone Medical Center, New York, NY

A phase I/II study of in situ vaccination with tremelimumab and IV durvalumab plus Poly-ICLC in subjects with advanced, measurable, biopsy-accessible cancers

- Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY

A phase II study to evaluate the clinical efficacy and safety of standards of care in combination with checkpoint blockade in patients with glioblastoma

- David A. Reardon, M.D., Dana-Farber Cancer Institute, Boston, MA

A phase II/I study of chemo-immunotherapy with Toll-like receptor 8 agonist motolimod and checkpoint blockade in subjects with recurrent, platinum-resistant ovarian cancer for whom pegylated liposomal doxorubicin is indicated

- George Coukos, M.D., Ph.D., University Hospital of Lausanne, Lausanne, Switzerland

TRIALS SUPPORTED WITH REAGENTS

A multi-epitope peptide vaccine plus Toll-like receptor agonists in melanoma patients, with evaluation of the injection site microenvironment for resected stage IIIB-IV

- Craig L. Slighflugg Jr., M.D., University of Virginia Health System, Charlottesville, VA

A phase I open label, multicenter, multi-ascending dose trial evaluating the safety, tolerability, and immunogenicity of intramuscular recombinant NY-ESO-1 protein with GLA-SE adjuvant in patients with unresectable or metastatic cancer expressing NY-ESO-1

- immune Design, Seattle, WA

A phase I study of cancer vaccine CHP-NY-ESO-1 in combination with Poly-ICLC in patients with esophageal cancer or malignant melanoma expressing NY-ESO-1

- Hiroshi Shiku, M.D., and Shinichi Kageyama, M.D., Mie University School of Medicine, Mie, Japan

A phase I study of concomitant WT1 antigen peptide and NY-ESO-1

- David O’Malley, M.D., The Ohio State University Wexner Medical Center, Columbus, OH
- Paul Sabbatini, M.D., Memorial Sloan Kettering Cancer Center, New York, NY

A preclinical mouse vaccination experiment to compare the effectiveness of Poly-ICLC to that of the more common QS-21

- Samuel Danishefsky, Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY

A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus novel adjuvant combinations

- Craig L. Slighflugg Jr., M.D., University of Virginia Health System, Charlottesville, VA

A phase I/IA study of vaccination with NY-ESO-1 protein, Poly-ICLC, and mogamulizumab in patients with advanced cutaneous T-cell lymphoma expressing NY-ESO-1

- Yuzuru Kanakura, Ph.D., and Hiroyoshi Nishikawa, M.D., Ph.D., Osaka University, Osaka, Japan

A phase II open label randomized study of Poly-ICLC-matured dendritic cells as an adjuvant for NY-ESO-1 and MELANA/MART-1 peptide vaccination compared to Montanide ISA-51 in patients with melanoma

- Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY

A pilot study of a novel multimodality immuno-chemotherapy platform for patients with advanced cutaneous T-cell lymphoma

- Catherine M. Diefenbach, M.D., NYU Langone Medical Center, New York, NY

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus Poly-ICLC in participants with melanoma

- Victor H. Engelhard, Ph.D., and Craig L. Slighflugg Jr., M.D., University of Virginia Health System, Charlottesville, VA

General research purposes (Poly-ICLC)

- Fathia Mami-Chouaib, Ph.D., Institut Gustave Roussy, Villejuif, France

General research purposes (Poly-ICLC)

- OncoPep, Inc., North Andover, MA

EVALUATION OF SAFETY AND IMMUNOGENICITY OF A MULTIPHOSPHAPETIDE VACCINE PLUS POLY-ICLC IN PARTICIPANTS WITH MELANOMA

- Evaluation of safety and immunogenicity of a multi-phosphapeptide vaccine plus Poly-ICLC in participants with melanoma

EVALUATION OF SAFETY AND IMMUNOGENICITY OF A MULTIPHOSPHAPETIDE VACCINE PLUS POLY-ICLC IN PARTICIPANTS WITH MELANOMA

- Evaluation of safety and immunogenicity of a multi-phosphapeptide vaccine plus Poly-ICLC in participants with melanoma

General research purposes (Poly-ICLC)

- OncoPep, Inc., North Andover, MA

CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT

LEENA GANDHI, M.D., PH.D.
CORRELATIVE AND LABORATORY STUDIES

Maha Ayyoub, Ph.D., Institut Gustave Roussy, Villejuif, France
Early-phase NY-ESO-1 clinical trials in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and monitoring of tumor-specific immune responses

Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY
Immunological monitoring for Cancer Vaccine Collaborative trials

Elke Jäger, M.D., Krankenhaus Nordwest, Frankfurt, Germany
Core support for NY-ESO-1 clinical trials

Daniel E. Speiser, M.D., University Hospital of Lausanne, Lausanne, Switzerland
Vaccination of melanoma patients (stage II-IV) with ImmuFact IMP321, tumor antigenic peptides, and Montanide

Daniela Valmori, Ph.D., Centre de lutte contre le Cancer Nantes-Atlantique, Nantes-Saint Herblain, France
Early-phase NY-ESO-1 clinical trials in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and monitoring of tumor-specific immune responses

Production of NY-ESO-1 overlapping peptides for use in a variety of trials

PolyPeptide Laboratories San Diego, San Diego, CA

Poly-ICLC stability testing

Oncovir, Inc., Washington, DC

LEVERAGED GRANTS

Special partnerships to explore novel preclinical and clinical studies in high-priority research areas.

James P. Allison, Ph.D., The University of Texas MD Anderson Cancer Center, Houston, TX, and Antoni Ribas, M.D., Ph.D., UCLA Medical Center, Los Angeles, CA
Cancer Immunology Translational Research Dream Team: Immunologic checkpoint blockade and adoptive T cell transfer in cancer therapy
In partnership with the Entertainment Industry Foundation/Cancer Research Institute

Carl H. June, M.D., and Gregory L. Beatty, M.D., Ph.D.
Perlman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Mesothelin-specific chimeric antigen receptor (CAR) T cell therapy for pancreatic cancer In partnership with the Lustgarten Foundation

Designated Grants
Grants to support research projects and public education and awareness initiatives for which, in most cases, donors have specifically raised funds.

American Association for Cancer Research Collaboration on Cancer Immunology Research

Timothy N.J. Bullock, Ph.D., University of Virginia Health System, Charlottesville, VA
Enhancing immune therapy for brain metastases with focused ultrasound
In partnership with the Focused Ultrasound Foundation

George Klein, M.D., D.Sc.*
Karolinska Institutet, Stockholm, Sweden
Studies on Epstein-Barr virus oncogenes and tumor suppressor genes, tumor immunology, and inhibition of tumor cell growth by stroma cells
In partnership with the Karolinska Institutet

Malcolm A.S. Moore, D.Phil.*
Memorial Sloan Kettering Cancer Center, New York, NY
The study of hematopoietic stem cells and progenitor populations in normal and cancer cells
Gar Reichman Laboratory

ANNUAL AWARDS
In addition to providing financial support to researchers and investigators, CRI also honors scientists and community leaders with achievement awards.

WILLIAM B. COLEY AWARD FOR DISTINGUISHED RESEARCH IN BASIC AND TUMOR IMMUNOLOGY

Annual prize given to one or more scientists whose discoveries in the fields of immunology or tumor immunology contribute to the advancement of immune system-based therapies for cancer.

Glenn Dranoff, M.D. ’Novartis Institute for BioMedical Research, Cambridge, MA

Alexander Y. Rudensky, Ph.D.*
Memorial Sloan Kettering Cancer Center, Ludwig Cancer Research, New York, NY

FREDERICK W. ALT AWARD FOR NEW DISCOVERIES IN IMMUNOLOGY

Prize honoring a former postdoctoral fellow in recognition of outstanding success in academia or industry for research that may have a potentially major impact on immunology.

Nina Bhardwaj, M.D., Ph.D.*
Icahn School of Medicine at Mount Sinai, New York, NY

AAICR-CRI LLOYD J. OLD AWARD IN CANCER IMMUNOLOGY

Award recognizes an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field.

Ronald Levy, M.D.*
Stanford University, Stanford, CA
In partnership with the American Association for Cancer Research

OLIVER R. GRACE AWARD FOR DISTINGUISHED SERVICE IN ADVANCING CANCER RESEARCH

Annual prize that recognizes the contributions of dedicated laypersons or organizations whose leadership has had a significant impact on cancer research.

Kenneth C. Frazier† Chairman and CEO, Merck & Co.
Lauren S. Veronis† Trustee, Cancer Research Institute, and Former President, Irvington Institute for Immunological Research
Powering Progress to Save Lives

Everything the Cancer Research Institute does to keep the momentum of scientific progress moving forward would not be possible without generous support from individuals, foundations, and corporations who are as passionate as we are to see an end to cancer as we know it. The outpouring of generosity has given us another record-breaking year of fundraising. Together, contributions to CRI from donors totaled $42.1 million last year—a signal of donor trust in CRI that will allow us to fund more research that translates into more lives saved.

From the thousands of individuals who make personal donations, to the passionate Team CRI members who plan fundraising events or participate in major endurance events around the country, to the families who donate yearly in memory of a loved one, and our trustees who give generously of both their time and money, no gift to CRI goes unappreciated. These contributions continue to make a difference in the life of the organization and the impact of its work.

“

When I ask my friends, family, and coworkers to support my fundraising efforts for CRI, I do so knowing that any gift, in any amount, is going to be used wisely, and ultimately will help us stop this terrible disease.

Priyanka Sewhani
Chair, CRI Young Philanthropists Council
Top Individual Fundraiser, 2016

Answer to Cancer Cycling Event

CRI CEO and Director of Scientific Affairs Jill O’Donnell-Tormey with former Revlon CEO Lorenzo Delpani and Revlon Ambassadors Olivia Wilde and Halle Berry; NBC Today Show host Matt Lauer at the Through the Kitchen Party; Seven-year-old Sage drew pictures of animals to raise funds for CRI; Team CRI runners in 2016 United Airlines New York Half Marathon; St. Louis-based T-shirt company Tee Turtle raised more than $54,000...
Supporting the Cause

The Cancer Research Institute’s ability to advance important science and facilitate the development of immunotherapies for all types of cancer is made possible through the generous support of our donors. Acknowledgments listed here reflect contributions of $1,000 and more made to CRI between July 1, 2015, and June 30, 2016.

$1,000,000+
Bristol-Myers Squibb
Anna-Maria and Stephen Kellen Foundation
MedImmune, Inc.
The Thompson Family Foundation

$500,000 - $999,999
The Hearst Foundations, Inc.
Merck
Multiple Myeloma Research Foundation, Inc.

$100,000 - $499,999
Merle S. Cahn Foundation
Clint Global Initiative
Estate of Prudence Cometa
Concern Foundation
Mr. and Mrs. Maurice J. Cunniffe
Fight Colorectal Cancer
Genentech
GlaxoSmithKline

$50,000 - $99,999
Amgen
AstraZeneca Pharmaceuticals LP
Estate of Stuart Sidney Bernard
Mr. and Mrs. Edgar R. Berner

$25,000 - $49,999
Agenus, Inc.
Baird
The Jeanne E. and Jacob A. Beazley Group
Borofsky
Frederic R. Coudert Foundation
Frederic R. Coudert Foundation

$10,000 - $24,999
Anonymous
Ronit and Marc Arginteanu Fund
Yacov Arnon
Alexandra Englund Audiberti
Rose M. Badgley Residuary Charitable Trust
Judy and Ron Baron
Charles N. Bartunek
Bonbright Family Foundation Trust
Mr. and Mrs. Charles Bronfman
Jeffrey A. Burki
Mr. and Mrs. Russell L. Carson
James M. Citrin

CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
I am so grateful for all the folks that are fundraising and actively raising awareness with the Cancer Research Institute, who are helping patients like me who, after failing all other clinical trials, are looking for the next option.

Ariella

Hodgkin lymphoma survivor treated with immunotherapy

Mr. and Mrs. Wesley McDonald
Estate of Sharon H. McGowan
Emil and Toby Meshberg Family Foundation Inc.
Morgan Stanley & Co.
Mr. and Mrs. Richard P. Morgenstem
Mr. and Mrs. Jacques C. Nordeman
North State Cancer League
Royce E. Oliver Jr.
Face, Inc.
PTD, Inc.
Mr. and Mrs. Jeffrey M. Peek
Harlan Petzl
The Research Foundation of CUNY
Carlos Rodriguez-Pastor
The Edward John and Patricia Rosenwald Foundation
Hillary and Wilbur Ross
Schaumburg Professional Firefighters BE
Adolph & Ruth Schnurmacher Foundation, Inc.
The Estate of Louise S. Schoenke
Lori Squire
Mr. and Mrs. Leonard N. Stern
Walter and Louise Sutcliffe Foundation
Michael Steven Swell
Liz Whitney Tippett Foundation, Inc.
Estate of Zeldah M. Utze
Mr. and Mrs. Ronald G. Weiner,
Perelson Weiner LLP
Wells Fargo
Robert D. Welsh
Lally Graham Weymouth and Joseph M. Cohen
Whiting Foundation
The Wiggins Foundation, Inc.

$5,000-$9,999
Abblovie Inc.
Gino Adamo's St. Joseph Dinner Dance
Alexander and Johannes Charitable Fund
Jane B. Allen
California Fund of the Hugh J. Andersen Foundation
Christopher Ankhavik
Anonymous (6)
Backman Research Foundation
C.R. Bard Foundation
Basin Holdings
Mercedes T. Bass
Charitable Corporation
Curtis Bergan
Cathie Black and Tom Harvey
Mr. and Mrs. James C. Blair
Franci J. Blassberg and Joseph L. Rice III
Borderland 2 on Twitch
The Henry W. Bull Foundation
Pat and Gil Caffray
Kevin Cook
Mr. and Mrs. Richard Corey
Mr. and Mrs. Ship Cressman
Danem Foundation
EisnerAmper LLP
Frank M. Ewing Foundation, Inc.
Mr. and Mrs. Carlos A. Ferrer
Tom Franco
Sam Friedman
Steven M. Galbraith
Mr. and Mrs. Nathan Gantcher
Terrell Gates
Cheryl & Edward S. Gordon Foundation

J. Ira and Nicki Harris
Family Foundation
Rochelle and David A. Hirsch Foundation, Inc.
Mr. and Mrs. William D. Hobbs
Innovative International Intelligence & Integration, LLC
Inovio Pharmaceuticals
Mr. and Mrs. George Kaufman
Richard and Suzanne Kayne Charitable Fund
Rachel Rutherford Englund Knapp
Mr. and Mrs. David H. Koch
Dr. Donald Kuspl
Charles and Margaret Levin
Foundation
Michael Litt
Audra M. Liu
W. Bruce Lunsford
D. Scott Mackesy
Mr. and Mrs. Christopher L. Marhofer
Evan McDonald-Stewart
Guillaume Mear
Joseph Mitola
Mitsubishi UFJ Securities (USA), Inc.
Dr. and Mrs. Malcolm Moore
Nandanson Charitable Foundation
Newgen Strategies and Solutions, LLC
NewLink Genetics Corporation
Northfield Bank
Morris W. Offit
Parkell Inc.
Chris Parry
Vickie and Rahn Pitzer
Pluralight
Verne C. Powell
Querrey Simpson Charitable Foundation
The Raether 1956 Charitable Trust Foundation
Kristin and Michael Reed
Family Foundation, Inc.
Reed-Lane, Inc.
Mr. and Mrs. Karl Roessner
Daryl and Steven Roth Foundation
Jami Rubin
Peter Craig Russell
Seaman Family Foundation
Kevin W. Sharer
Michael Charles Sharp
Mr. and Mrs. Paul H. Sherry
Mr. and Mrs. Brian Sir

Mr. and Mrs. Craig Smith
Geraldine and Ernest Smith
Socket Telecom LLC
Michael Sorensen
Stainman Family Foundation
Dr. David Staunton
Mr. and Mrs. Allan Stern
Mr. and Mrs. Douglas Stone
Sharon and Tom Teles
The Thorn Family Foundation, Inc.
Elizabeth and Jim Tinsman
Venable, Bell & Partners LLC
Paul H. Volpe Revocable Trust
Jeff Webb
Harriet and Ronald Weintraub
Mr. and Mrs. James C. Zelter

$1,000-$4,999
24-7 Auto Transport, Inc.
Qasim Abbas
Richard Abbey
Debbie H. Abbott
Kedar Abhyankar
Abbey and Richard Aborn
Joseph Mitola
Mitsubishi UFJ Securities (USA), Inc.
Dr. and Mrs. Malcolm Moore
Nandanson Charitable Foundation
Newgen Strategies and Solutions, LLC
NewLink Genetics Corporation
Northfield Bank
Morris W. Offit
Parkell Inc.
Chris Parry
Vickie and Rahn Pitzer
Pluralight
Verne C. Powell
Querrey Simpson Charitable Foundation
The Raether 1956 Charitable Trust Foundation
Kristin and Michael Reed
Family Foundation, Inc.
Reed-Lane, Inc.
Mr. and Mrs. Karl Roessner
Daryl and Steven Roth Foundation
Jami Rubin
Peter Craig Russell
Seaman Family Foundation
Kevin W. Sharer
Michael Charles Sharp
Mr. and Mrs. Paul H. Sherry
Mr. and Mrs. Brian Sir

THE DONNY G MEMORIAL GOLF TOURNAMENT

THE CANCER RESEARCH INSTITUTE 2016 ANNUAL REPORT
It was an honor to play a small role in the process that will sustain cancer immunotherapy into the future.

Julian Suchman
Team CR8 runner,
TCS New York City Marathon
Mr. and Mrs. Robin Hayes
Ms. Gale Hayman and
Dr. Richard S. Bockman
Head Family Trust
Donald B. Hebb Jr.
Margaret J. Heiser
Alexandra B. Helms
Donald B. Hebb Jr.
Head Family Trust
Brenda Kulick
Ivan Kriakov
John Krenicki
Mr. and Mrs. Richard F. Kossik
Miss Laine Koman
Koko Fitclub of Minnesota
Robert Klett
Jerry Kleinman
Mr. and Mrs. Jerry Lis
Craig B. Thompson, M.D.
The Sue and Eugene Mercy, Jr.
Foundation, Inc.
Lasantha Pathirana
Lasantha Pathirana
Joseph A. Patrick Foundation, Inc.
Lasantha Pathirana

William Mansfield
Mr. and Mrs. Michael Maranto
Mariel Foundation
Beverly and John Marino
Jane Martin and Stuart Katz
Mr. and Mrs. Regge A. Martin
Mr. and Mrs. Steve Martin
Richard A. Martini
Martins Construction Corporation
Michael M. Marzban
Jeffrey A. Mason
Mr. and Mrs. Allen R. Mass
Dr. Philip Mastman
Ellen C. Mathias
John D. Mauro
Jeffrey S. Mao
Roy ‘Rem’ Mayes
Dorothy McCabe and Lee Kentz
David McElligott
Christopher Magagnall
Kate A. McKay
Christine McKenney
Dr. Vernon L. Pankonin

Pamela Anne Murphy
Vanitha Murugesan
Maria Isabel Nadal De Puigdorfa
Jenks Neckler Charitable Fund
Deborah Newman-Smith
Kevin K. Nickel
Barbara Nielsen
Jon Nite
Norwalk High School
Notre Dame Academy
John Novak
Jeffrey Nuechterlein
Brandon Nutter
Rebecca and Douglas Oletz
Melissa and Charles O’Brien
Mr. and Mrs. Gregory A. Odle
Christine Ogata
Carolyn J. O’Hara
Mr. and Mrs. James A. Olson
Mr. and Mrs. John Orlando
Daniel O’Shaughnessy
Twila I. O’Sullivan
Elma and Fred Otto
Joe Ozie
Packer Family Charitable Fund
Michael Palmer
Yvonne S. Palmer
Dr. Vernon L. Pankonin
Lee A. Paree
Darryl F. Parrish
Kelly and Gerry Pasciuco
Lisathania Patihana
Joseph A. Patrick Foundation, Inc.
Camilo Patignani
Paterson Companies Inc.
China Pavilion
Alan Peterson
Jeffrey A. Peterson
Dr. and Mrs. Frank Pettit
Pew Charitable Trusts
John C. Peyrebrune
Mr. and Mrs. Herald L. Ritch
Robert P. Rittereiser
Anna Rockler
Rebecca Rogers
Dr. and Mrs. Leon Root
Steven M. Rosenberg Fund
Mrs. Abraham Rosenthal
Jane Rosenthal and Craig Hatkoff
Barry D. Roy
Francisco R. Roy
Richard J. Royer
Laurette Rupe
Robert Rushon

Mr. and Mrs. Richard C. Hosley II
Eric Howard
John Howard
Hudson Americas L.P.
Kathleen Hughes
Martiza Hurtado
HxW Environmental Consultants
Ideal Image of Delaware
Capt. Scott Ingram
Integris, LLC
Mr. and Mrs. Marc J. Isaacs
Mr. and Mrs. Seymour Israel
E. Marion Jacknow
Deborah and Arthur Jacobson
The James Jacobson Family Fund
Kate and Jeff Janineck
George and Janet Jaffin Foundation
Jakal Booster Club
Janklow Foundation
Elizabeth M. Jennings
Tina Jicha
Donald Joh
Johri Family Charitable Foundation
Anne and Johnny Jones
Austin Jones
JP Morgan Chase Foundation
Rebecca and Michael Juneau
Dr. Basim Kadam
Mr. and Mrs. Neil R. Kardos
Mr. and Mrs. Howard Kaye
Mr. and Mrs. Jerrel W. Kee
Mr. and Mrs. Tenny Keller
Mr. and Mrs. William Keller
Edna Kelley
Veronica and Ray Kelly
Mr. and Mrs. Richard Kerns
Keurig Green Mountain
Mr. and Mrs. Bradley D. Kevem
Alena Kim
Ken Kinslow
William Kissling
Mr. and Mrs. Brandon Kister
Mark E. Klein
Jerry Kleinman
Robert Klett
Shannon Klue
Koko Flats Club of Minnesota
Miss Laine Koman
Mr. and Mrs. Richard F. Kossik
Takashi Kousaka
Andrew Kratz
John Krenicki
Ivan Kriakov
Brenda Kulick
Mr. and Mrs. Kevin Kuntz
Perry A. Kupietz
Mr. and Mrs. David P. Kusel
Mark Kwan
Sheila Labrecque
Mr. and Mrs. Benjamin Lambert
Harlos R. Larrowe
Laser Image
Carey F. Latthrop
The Jeremy Lau Fund
Dr. Lena and Professor Pernest Lawe
Martha and Drahomir Lazar
The League of Legends Community
Lauren Ledford
Elizabeth Lee
Michelle Leeds
Mr. and Mrs. Ben LeKowitz
Morris and Lillie Leibowitz
Charitable Trust
Mr. and Mrs. Craig Lemle
David Lender
Dr. and Mrs. Philip R. Lesorgen
Mr. and Mrs. Francis L’Esperance
Dr. Andrei Levin
Richard and Emily Levin Foundation
John S. Levy
Mary Lynne Levy
William Li
Life Time Marketing, LLC
Anthony Lin
Tullia Linden, M.D., Ph.D., and
Craig B. Thompson, M.D.
Mr. and Mrs. Jerry Lis
Daniel C. Litchfield
Chris Lloyd
Brad Loncar
Heather Long
Longboard Asset Management LLC
Timothy and Leslie Lucas
Charitable Fund
William C. Lucia
Brian Luu
Donald L. Lundholm
Peter Lyon
Lynd L. Lyons
Mr. and Mrs. Bruce R. MacDonald
Madame LLC
Dr. Thomas Mack
Robert S. Madden
Madhatter’s Tea Party
Thomas Maheras
Chris & Melody Malachowsky
Family Foundation
Laurie and Jay Mandelbaum

It was an honor to play a small role in the process that will sustain cancer immunotherapy into the future.
The Rust Family Foundation
Sallay Family Fund
Stanley Saltzman
Francine M. Sandoval
Mr. and Mrs. Adarsh Sarma
Rose Ann Scamandrelia
Scanning America, Inc.
Heather Schimmel
Schüter Systems L.P.
William O. Schraine
Lauren A. Schmidt
Rick Schnall
Karen A. and Henry P. Schneider
Mike Schoebein
June and Paul C. Schorr III
Dr. David N. Schrier
Schulman Family Foundation
Henry C. Schulte and Virginia M. Schulte Foundation
Larry R. Schuneman
James M. Scriver
Brian Searcy
Hooman Sedighi
Mr. and Mrs. Thomas L. Seifert
Karen Shapiro
Stephen Shapiro
Jane Sharp
Dan Shedrick
Cynthia Sheets
Shell Oil Company Foundation
Rocky John Sherer
Raechele B. Sherman
Jonathan Shipman
The Susan S. Shiva Foundation
Showin’ for a Cure
Mr. and Mrs. Brian D. Silverman
Anne Silverstein
Edward R. Simmons
Simplistics, Inc.
The Simpson Foundation
Linda G. Singer
Nate Sleeper
Laura J. Sloate
Lois V. Smigel
Mr. and Mrs. Gordon H. Smith
Mr. and Mrs. Jeffrey Q. Smith
Mary F. Smith Family Foundation
Nora M. Smith
Patrick Smith
Mr. and Mrs. Scott Sokol
Mr. and Mrs. Howard Solomon
Solutions By Design II, LLC
Anne Spencer
William Spero
Michael Spitzenberger
Kristen Sproat Colley
St. Luke’s Lutheran Church
Paul Stagg
Edgar Stanley
Bonnie M. and Robert J. Stapleton
The Honorable and
Mrs. Kenneth W. Starr
Michael Starr
Mary K. Steffens Foundation
Beatrice Stern
Patricia Stohler
Bonnie and Tom Strauss
Stuntz Family Foundation
Mayo S. Stuntz
Sweet/Polak Charitable Fund
Marc Tabah
Mr. and Mrs. Kok Chor Tan
Jesycia Tang
Joshua L. Targoff
Nicki Taylor and the Cuddlebugs
Jean and Kenneth Telljohann
Tennis League Network, LLC
Texarkana Jeep Junkies Club
Mr. and Mrs. Jeffery Thomas
Marc Thomson
Thomspon Reuters
Mr. and Mrs. Andrew H. Tisch
Dr. and Rev. David C. Tontonoz
William Topham
Mr. and Mrs. Alex Toppin
Alain Tranchemontagne
Mr. and Mrs. John Trousdale
Paul Trunk
TTX Company
Mary Ann Tuft
Timothy F. Turitto
Allen M. Turner
Dr. Lynn H. Turner
USPA Liz Freel Classic
Nancy and Jim Utzki
Utility Contracting Co.
Mr. and Mrs. Jeffrey K. Valentine Sr.
Anne and Philip Vander Haar
Csaba Vador
J.J. Venturini
Village of Long Creek
Maintenance Corporation
The Villages Theater Company
Millie Viqueira and Steven Miller
VMware Foundation
John Vogel
Mr. and Mrs. Lance Volland
The Kathleen B. and Charles R.
Walgreen III Foundation
Robert W. Walker
Richard N. Walsh
Barbara Walters
Carrie L. Walworth
Jeff Ware
Joseph Warren
Carolyn and David Wasserman
Watermark Learning
Sandra J. Watter
Web Decisions Group
Steven E. Weigand
The Weingarten Schnitzer Foundation
Helen and Tom Welting
Wendell Family Foundation
S. Kyle Wesson
Elizabeth G. Weymouth
Gerald I. White
The Wild Unknown
David T. Wiley
Joanna Williams
Greg Wilson
Patricia M. Wilson
Mr. and Mrs. Dennis Winans
Greg Witt
Michael J. Wisdom
The Wise Family Trust
Carole and Michael Witte
Michael Worsky
Elaine and Jim Wolfensohn
Gregg S. Wolpert
Mr. and Mrs. William Worthington
WowToyz
Melissa Yannis-Grand
Stephen Yegelwel
Strauss Zeinick
Zenith Ventures, Inc.
J.L. Zrebiec
Mr. and Mrs. Jeffrey Zucker
Joan R. Zucker
Marc Zuckerman
Barry Zurbuchen

Helen Coley Nauts Society

The Helen Coley Nauts Society recognizes donors who have included the Cancer Research Institute in their estate plans. Through deferred gifts, bequests, trusts, and other planned giving instruments, these thoughtful individuals safeguard the Institute’s financial future. The Helen Coley Nauts Society is named in honor of Helen Coley Nauts, CRI’s founder. If you would like to learn more about making a planned gift, please contact Rupinder Kaur at rkaur@cancerresearch.org or (212) 688-7515.

Estelle Abas
Peter Adams
Abigail Alderman
Olga Aleskas
Mildred E. Alexander
Frederick E. Allard
Edith M. Amateau
Peggy Anderson
Anonymous (6)
Frances Antopol
Freda S. Armstrong
Grace Arnold
Geneva A. Arthur
Millie L. Arvanites
Ruth Ascher
Virginia and Rex Ashdown
Lee Ashman
Belle Ashman
Alice Auerbach
Norman W. Austin
Jeanne Avegno
Else Baier
Maureen and Charles Baker
Olga Baker

ANNUAL AWARDS DINNER AT THE METROPOLITAN CLUB #WHITEOUTCANCER EVENT AT MEDIMMUNE/ASTRAZENECA, AND ANSWER TO CANCER CYCLING TEAM BRISTOL-MYERS SQUIBB
Louise G. Lane  
Caryl Lou Langford  
Elizabeth S. Larkin  
Anne-Marie LaValle  
 Mildred Leffler  
Florence and Edgar Leslie  
Polly Annenberg Levee  
James F. Levens  
Frances Leventritt  
Betty Lou Levin  
Esther Levit  
Beatrice Levy  
Simon Lifshatz  
Francis R. Linden  
Harvey A. Linden  
Patricia A. Lindner  
George H. Linds skog  
Roseline Lissak  
David Madsen  
Hennetra Malbin  
Herbert J. Maletz  
Isabelle C. Malone  
Anna Malowany  
John Malowany Trust  
Fe rine Magialardo  
Meyer Marcus  
B.M. Marvin  
Geneviève Martin  
Louemma Martin  
Lowell A. Martin  
Raleigh L. Martin  
Blanca Mattalia-Wyzkowski  
Mildred Matz  
Donald Maurer  
Lourdes Mayuyu  
Margaret Mazey  
Michael T. McBride  
Helen McCann  
Cecil McC l eron  
Annette McDonald  
Sharon H. McGowan  
J. Donald McKinney Jr.  
Norma J. McPherson  
Jan Mears  
Grace Muriet-Mecchi  
Joan Metteson  
Nancy Jeanne Merkel  
Sidney Meskin  
Ethel L. Meyer  
Ezilda Michel  
HeLEN T. Mck EVIrt  
Dorothy Mae Miller  
Wayne D. Miller  
Alex Mitchell  
Malha Mohammed  
Mr. and Mrs. Charles G. Moore  
Janet P. Morgan  
Maza D. Morris  
Louise and Peter Moseychuk  
Bryan A. Muenzen  
Alexander Munchw eiler  
Irene R. and Martin F. Murphy  
Judith K. Murphy  
Kathryn T. Murphy  
Thomas P. Murray  
Naomi Myers  
Mayumi Nakagawa and John K. Lai  
Rita Nasser  
Alice A. Nauts  
Patricia Navarro  
Paula M. Neal  
Barbara Lynne Nelson  
Rose E. Nelson  
Jean Marie Newcomer  
Freda E. Newton  
William E. Newton  
Helene H. Nichols  
B ernard N. Niewoehner  
Geneva W. Nolen  
Jacques C. Norderman  
Mary M. Nowak  
Mary Nusz  
Dorothy B. Nurlick  
Margaret M. and Harry A. Oak  
Nora Odets  
Arvilla Ogden  
Michaële A. Ogibene  
Roselyn R. Oikinen  
Alice Orlích  
Mary O'Rourke  
Anna and Paul Oshwald  
Albert Ottinger  
Lily Pace and Floyd Pace  
Marjorie W. Packwood  
Emra N. Panfilio  
Andrew Reid Paton  
Eleanor T. Patterson  
Carmen F. Patti  
Foster Clae Patton  
Frederick V. Payne  
Nancy Elizabeth Pease  
April Peck  
Donald H. Pepe  
Agnes Phelps  
Elizabeth F. Phillips  
John Piercy  
Harriet-Anne Pierson  
Rochelle Pinz  
Cynthia J. Plat t  
Dorothy Plumb  
Mabel Plunkett  
Nick J. Poakea  
David M. Polen  
Esther Posin  
Richard Potruch  
Despina Poulos  
Clifford Presky  
Joyce A. Prime  
Dorothy S. Pitchard  
Kevin L. Smith  
Patricia Smith  
Willie Mae Smith  
Ruth Sneve  
Vera Marie Sridner  
Estherina and Harold Sohmer  
F red E. Spencer  
Jacqueline Spencer  
William Sprenger  
Remy R. Sprouse  
Brenda M. St. James  
Jerald J. Steinberg  
Leopold Stein decker  
Anna Steph an  
Robert L. Stevens  
Mary Malcolm Stiles  
John Strong  
Fay Strat and Laurence Cecil Strat  
Frieda Coons Studley  
Dorothy H. Sullivan  
Myrtle B. Summers  
Agnes Margaret Sunley  
John Supon  
Mary and James Suthard  
Mary Carol Talercio  
Maureen Tann Each  
Melvin G. Taylor  
George C. Thomas Jr.  
Carl E. Thomas  
Virginia Schuettpeltz  
Hellen R. Schutt  
Ruth Schwartzman  
Rev. Harold Bend Sengdwick  
Dorothy K. Sevcovic  
Francine Sevall  
Clara Senk  
Natalie Shebs  
Dorothy M. Sheese  
Margaret Sheets  
Donald V. Vl eman  
Myrthe and Antoine L. Vinel  
Anne D. Vinton  
Paul H. Volpe  
Linda Vorno  
Esther and Stanley Wade  
Ethel Wagner  
David Walker  
Robert B. Walker  
Thomas Walsh  
Julia Wätz  
Lea Ward  
Irene M. Watkins  
Dorothy Waugh  
Ione A. and Albert L. Weickert  
Rose A. Wilhelm  
Elizabeth A. Weiser  
Leonard Weiss  
Robert P. West  
Anna M. Wheeler  
Lois Helen Weatherly  
Agneila L. Widmer  
Geneva K. Widmer  
Margaret Wiegandt  
Saul J. Wiener  
Loretta M. Willett  
Berta M. Willison  
Elizabetha H. Wilk  
Josephine H. Williams  
Ora Brown Windle  
Mr. and Mrs. Norman J. Woodhams  
Frederick W. Woodward  
Carolyn and Bill Woody  
John A. Wootton  
Josephine Wootton  
Ettie Wright  
Ethel Wagner  
Marion E. Youngberg  
Mr. and Mrs. Everett L. Weissner  
Clayton White  
Mr. and Mrs. Brian D. Silverman  
Mr. and Mrs. Marvin Stillman  
Mr. and Mrs. Milton S. Rubin  
Clifford M. Rutter  
Joyce Schumr  
Mr. and Mrs. Sydney Shuman  
Mr. and Mrs. Jonas J. Rieter  
Mr. and Mrs. Milton S. Rubin  
Mr. and Mrs. Ira M. Boskey  
Brian M. Brewer  
Lauren B. Burns  
Harriet E. Charles  
Mr. and Mrs. Irving Cohen  
Aileen Cole  
Selma Davidson  
Archibald M. Denny III  
Mr. and Mrs. Stephen C. Elkin  
Rhoda Fischman  
Anne E. Gentile  
Mr. and Mrs. Gary R. Ginsberg  
Mr. and Mrs. Leonard Gold  
Oliver R. Grace Jr.  
Rena A. Harris  
Harvey A. Herbert  
Mr. and Mrs. Stephen M. Keilen  
Col. Richard C. Kowalski  
Mr. and Mrs. Helan Rixter  
Mr. and Mrs. Michael Levy  
Charles J. Lurie  
Mr. and Mrs. Charles Lytle III  
Thomas G. Mendel l  
Mr. and Mrs. Arthur Nasso  
J aques C. Nordenman  
Bernardette Nuzzo  
Maxwell D. Osborne  
Esther Ravin  
Mr. and Mrs. Jonas J. Rieter  
Mr. and Mrs. Milton S. Rubin  
Clifford M. Rutter  
Joyce Schumr  
Mr. and Mrs. Sydney Shuman  
Mr. and Mrs. Brian D. Silverman  
Mr. and Mrs. Marvin Stillman  
Mr. and Mrs. Milton S. Rubin  
Clifford M. Rutter  
Joyce Schumr  
Mr. and Mrs. Sydney Shuman  
Mr. and Mrs. Brian D. Silverman  
Mr. and Mrs. Marvin Stillman  
Mr. and M.
Donor trust is something we value above all else. To earn and maintain this trust, we hold ourselves to the highest standards of accountability and transparency when communicating the financial health of this organization. Seeking to extract maximum impact from every dollar donated, we fund strategically and invest responsibly, keeping an eye to the long view of progress while remaining nimble enough to respond to new opportunities. Our financial records are kept according to best accounting practices, and we open our books annually for inspection and verification by independent auditors.

EisnerAmper has conducted an independent audit of the Cancer Research Institute’s financial activities for fiscal year 2016 (July 1, 2015, to June 30, 2016). We provide highlights here, and you can access our complete audited financial statements on our website at cancerresearch.org/financials.

The continued financial strength of this organization stems not only from the generosity of our donors, but also from the rigorously high standards of accountability to which we hold ourselves.

Alfred R. Massidas
Chief Financial Officer
Providing Expert Oversight

Volunteer scientific and business leaders help the Cancer Research Institute, not only through academic and financial support, but also through astute governance and active participation in the organization’s initiatives.

BOARD OF TRUSTEES

CHAIRMEN

Paul C. Shiverick
Co-Founder
Seminole Management Company, Inc.
New York, NY

Andrew K. Tsai
Managing Principal
Chalkstream Capital Group, L.P.
New York, NY

VICE CHAIRMEN

Edgar R. Berner
Partner
John Lang, Inc.
New York, NY

John B. Fitzgibbons
Chairman and CEO
Basin Holdings US LLC
New York, NY

Donald J. Gogel
Chairman and CEO
Clayton, Dubilier & Rice, LLC
New York, NY

Jacques C. Nordeman
Chairman
Nordeman Grimm, Inc.
New York, NY

Andrew M. Paul
Managing General Partner
Enhanced Equity Funds
New York, NY

TREASURER

Glenn J. DeSimone
Greenwich, CT

Lief D. Rosenblatt
Partner
ENE Investco Management
New York, NY

SECRETARY

John E. Eckerson
Rye, NY

Frank V. Sica
President
Tailwind Capital
New York, NY

Vice Chairman, CRI Board of Trustees

Margot E. Freedman
Larchmont, NY

James A. Stern
Chairman and Founder
The Cypress Group, LLC
New York, NY

Andrew M. Paul
Managing General Partner
Enhanced Equity Funds
New York, NY

Donald J. Gogel
Chairman and CEO
Clayton, Dubilier & Rice, LLC
New York, NY

Michael M. Kellen
Director of First Eagle Holdings, Inc.
Vice Chairman of First Eagle Investment Management, LLC
New York, NY

Diane Tuft
New York, NY

Maurice J. Cunniffe
Chairman and CEO
Vista Capital Corporation
Greenwich, CT

Michael B. Targoff
Vice Chairman of the Board of Directors
Loral Space & Communications
New York, NY

W. Robert Dahl
Principal
WRD Capital
Darien, CT

Board of Trustees

Stamford, CT

Sean P. Fahey
Founding Member and Co-Chief Investment Officer
Claren Road Asset Management
New York, NY

Brian Riano
Co-Founder and CEO
Claren Road Asset Management
New York, NY

Glenn J. DeSimone
Greenwich, CT

Margot E. Freedman
Larchmont, NY

John E. Eckerson
Rye, NY

Chancellor, CRI Board of Trustees

Oliver R. Grace Jr.
President
Associated Asset Management, Inc.
Palm Beach, FL

Sandra Coudert Graham
Oyster Bay, NY

Lauren S. Veronis
New York, NY

Michael M. Kellen
Director of First Eagle Holdings, Inc.
Vice Chairman of First Eagle Investment Management, LLC
New York, NY

Diane Tuft
New York, NY

Michael B. Targoff
Vice Chairman of the Board of Directors
Loral Space & Communications
New York, NY

Lauren S. Veronis
New York, NY

Ronald G. Weiner
President
Perelson Weiner LLP
New York, NY

CRI trustees are fully engaged in our mission because each of us believes in the potential of immunotherapy to conquer all cancers, and each has seen how CRI is able to transform this potential into reality for many cancer patients today.

John B. Fitzgibbons
Chairman and CEO
Basin Holdings US LLC
Vice Chairman, CRI Board of Trustees
<table>
<thead>
<tr>
<th>Individual</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Philip D. Greenberg, M.D.</td>
<td>University of Washington School of Medicine and Fred Hutchinson Cancer Research Center Seattle, WA</td>
</tr>
<tr>
<td>Axel Hoos, M.D., Ph.D.</td>
<td>GlaxoSmithKline Collegeville, PA</td>
</tr>
<tr>
<td>Patrick Huru, M.D.</td>
<td>The University of Texas MD Anderson Cancer Center Houston, TX</td>
</tr>
<tr>
<td>Elizabeth M. Jaffe, M.D.</td>
<td>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Baltimore, MD</td>
</tr>
<tr>
<td>Michael Kalos, Ph.D.</td>
<td>Eli Lilly &amp; Company New York, NY</td>
</tr>
<tr>
<td>Michael Karin, Ph.D.</td>
<td>University of California, San Diego, La Jolla, CA</td>
</tr>
<tr>
<td>Carl H. June, M.D.</td>
<td>Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA</td>
</tr>
<tr>
<td>Michael Kalos, Ph.D.</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Michael Karin, Ph.D.</td>
<td>New York, NY</td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td>San Diego, La Jolla, CA</td>
</tr>
<tr>
<td>John M. Kirkwood, M.D.</td>
<td>University of Pittsburgh Cancer Institute Pittsburgh, PA</td>
</tr>
<tr>
<td>George Klein, M.D., D.Sc.</td>
<td>Karolinska Institute Stockholm, Sweden</td>
</tr>
<tr>
<td>Alexander Knuth, M.D.</td>
<td>National Center for Cancer Care and Research, Hamad Medical Corporation Doha, Qatar</td>
</tr>
<tr>
<td>Lewis L. Lanier, Ph.D.</td>
<td>University of California, San Francisco San Francisco, CA</td>
</tr>
<tr>
<td>Hyam I. Levitsky, M.D.</td>
<td>Juno Therapeutics Seattle, WA</td>
</tr>
<tr>
<td>Dan R. Littman, M.D., Ph.D.</td>
<td>NYU Langone Medical Center New York, NY</td>
</tr>
<tr>
<td>Nils Lonberg, Ph.D.</td>
<td>Bristol-Myers Squibb Milpitas, CA</td>
</tr>
<tr>
<td>Tak W. Mak, Ph.D., D.Sc., FRSC</td>
<td>The Campbell Family Institute for Breast Cancer Research at Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada</td>
</tr>
<tr>
<td>Philippa C. Marrack, Ph.D.</td>
<td>National Jewish Health and the University of Colorado Denver, Denver, CO</td>
</tr>
<tr>
<td>Cornelis J.M. Meijer, M.D., Ph.D.</td>
<td>Leiden University Medical Center Leiden, The Netherlands</td>
</tr>
<tr>
<td>Ira Mellman, Ph.D.</td>
<td>Genentech South San Francisco, CA</td>
</tr>
<tr>
<td>Malcolm A.S. Moore, D.PHIL</td>
<td>Memorial Sloan Kettering Cancer Center New York, NY</td>
</tr>
<tr>
<td>Lee Nadler, M.D.</td>
<td>Dana-Farber Cancer Institute Boston, MA</td>
</tr>
<tr>
<td>Kunle Oludniyi, M.D., Ph.D.</td>
<td>Roswell Park Cancer Institute Buffalo, NY</td>
</tr>
<tr>
<td>Drew M. Pardoll, M.D., Ph.D.</td>
<td>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Baltimore, MD</td>
</tr>
<tr>
<td>Klaus Rajewsky, M.D.</td>
<td>Max-Delbrück Center for Molecular Medicine Berlin, Germany</td>
</tr>
<tr>
<td>Anjana Rao, Ph.D.</td>
<td>La Jolla Institute for Allergy and Immunology, Sanford Consortium for Regenerative Medicine La Jolla, CA</td>
</tr>
<tr>
<td>Jeffrey V. Ravetch, M.D., Ph.D.</td>
<td>The Rockefeller University New York, NY</td>
</tr>
<tr>
<td>Alexander V. Rudensky, Ph.D.</td>
<td>Memorial Sloan Kettering Cancer Center New York, NY</td>
</tr>
<tr>
<td>Bijn Safai, M.D., D.Sc.</td>
<td>New York Medical College Valhalla, NY</td>
</tr>
<tr>
<td>Shimon Sakaguchi, M.D., Ph.D.</td>
<td>immunology Frontier Research Center, Osaka University Osaka, Japan</td>
</tr>
<tr>
<td>Lawrence E. Samelson, M.D.</td>
<td>National Cancer Institute, NIH Bethesda, MD</td>
</tr>
<tr>
<td>Hans Schreiber, M.D., DMSc., Ph.D.</td>
<td>The University of Chicago Chicago, IL</td>
</tr>
<tr>
<td>Ton N. Schumacher, Ph.D.</td>
<td>The Netherlands Cancer Institute and Kite Pharma Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Craig L. Slingluff Jr., M.D.</td>
<td>University of Virginia School of Medicine Charlottesville, VA</td>
</tr>
<tr>
<td>Mark J. Smyth, Ph.D.</td>
<td>QIMR Berghofer Medical Research Institute Queensland, Australia</td>
</tr>
<tr>
<td>Pramod K. Srivastava, M.D., Ph.D.</td>
<td>University of Connecticut Health Center Farmington, CT</td>
</tr>
<tr>
<td>Susumu Tonegawa, Ph.D.</td>
<td>Massachusetts Institute of Technology Cambridge, MA</td>
</tr>
<tr>
<td>Emil R. Unanue, M.D.</td>
<td>Washington University School of Medicine St. Louis, MO</td>
</tr>
<tr>
<td>Ulrich H. von Andrian, M.D., Ph.D.</td>
<td>Harvard Medical School and Boston Children's Hospital Boston, Boston; The Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University Cambridge, MA</td>
</tr>
<tr>
<td>Robert H. Vanderheide, M.D., DPhil</td>
<td>Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA</td>
</tr>
<tr>
<td>Hao Wu, Ph.D.</td>
<td>Boston Children's Hospital and Harvard Medical School Boston, MA</td>
</tr>
<tr>
<td>Cassian Yee, M.D.</td>
<td>Johns Hopkins University School of Medicine Baltimore, MD</td>
</tr>
<tr>
<td>Antoni Ribas, M.D., Ph.D.</td>
<td>UCLA Medical Center Los Angeles, CA</td>
</tr>
<tr>
<td>Michel Sadelain, M.D., Ph.D.</td>
<td>Memorial Sloan Kettering Cancer Center New York, NY</td>
</tr>
<tr>
<td>Jonathan S. Cebon, Ph.D., FRACP</td>
<td>Austin Health/Ludwig Cancer Research Melbourne, Australia</td>
</tr>
<tr>
<td>George Coukos, M.D., Ph.D.</td>
<td>University Hospital of Lausanne (CHUV) Lausanne, Switzerland</td>
</tr>
<tr>
<td>Lawrence Fong, M.D.</td>
<td>University of California San Francisco San Francisco, CA</td>
</tr>
<tr>
<td>Dirk Jäger, M.D.</td>
<td>National Center for Tumor Diseases, University of Heidelberg Heidelberg, Germany</td>
</tr>
<tr>
<td>Elizabeth M. Jaffe, M.D.</td>
<td>Johns Hopkins University School of Medicine Baltimore, MD</td>
</tr>
<tr>
<td>Robert H. Vanderheide, M.D., DPhil</td>
<td>Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA</td>
</tr>
<tr>
<td>Robert H. Vanderheide, M.D., DPhil</td>
<td>Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA</td>
</tr>
<tr>
<td>Kunle Oludniyi, M.D., Ph.D.</td>
<td>The Roswell Park Cancer Institute Bufalo, NY</td>
</tr>
<tr>
<td>Neil H. Segal, M.D., Ph.D.</td>
<td>Memorial Sloan Kettering Cancer Center New York, NY</td>
</tr>
<tr>
<td>Andrew G. Sikora, M.D.</td>
<td>Baylor College of Medicine Houston, TX</td>
</tr>
<tr>
<td>Craig L. Slingluff Jr., M.D.</td>
<td>University of Virginia Cancer Center Charlottesville, VA</td>
</tr>
<tr>
<td>Marcel R.M. van den Brink, M.D., Ph.D.</td>
<td>University of Connecticut Health Farmington, CT</td>
</tr>
<tr>
<td>Dirk Jäger, M.D.</td>
<td>National Center for Tumor Diseases, University of Heidelberg Heidelberg, Germany</td>
</tr>
<tr>
<td>Elizabeth M. Jaffe, M.D.</td>
<td>Johns Hopkins University School of Medicine Baltimore, MD</td>
</tr>
<tr>
<td>Carl H. June, M.D.</td>
<td>Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA</td>
</tr>
<tr>
<td>E. John Wherry, Ph.D.</td>
<td>Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania Philadelphia, PA</td>
</tr>
<tr>
<td>Michael Kalos, Ph.D.</td>
<td>New York, NY</td>
</tr>
<tr>
<td>Eli Lilly &amp; Company New York, NY</td>
<td>Buenos Aires, Argentina</td>
</tr>
<tr>
<td>Michael Karin, Ph.D.</td>
<td>New York, NY</td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td>San Diego, La Jolla, CA</td>
</tr>
<tr>
<td>Michael Kalos, Ph.D.</td>
<td>New York, NY</td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td>San Diego, La Jolla, CA</td>
</tr>
<tr>
<td>Philip D. Greenberg, M.D.</td>
<td>University of Washington School of Medicine and Fred Hutchinson Cancer Research Center Seattle, WA</td>
</tr>
<tr>
<td>Axel Hoos, M.D., Ph.D.</td>
<td>GlaxoSmithKline Collegeville, PA</td>
</tr>
<tr>
<td>Patrick Huru, M.D.</td>
<td>The University of Texas MD Anderson Cancer Center Houston, TX</td>
</tr>
<tr>
<td>Elizabeth M. Jaffe, M.D.</td>
<td>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine Baltimore, MD</td>
</tr>
<tr>
<td>Michael Kalos, Ph.D.</td>
<td>Eli Lilly &amp; Company New York, NY</td>
</tr>
<tr>
<td>Michael Karin, Ph.D.</td>
<td>New York, NY</td>
</tr>
<tr>
<td>University of California, San Diego</td>
<td>San Diego, La Jolla, CA</td>
</tr>
<tr>
<td>John M. Kirkwood, M.D.</td>
<td>University of Pittsburgh Cancer Institute Pittsburgh, PA</td>
</tr>
<tr>
<td>George Klein, M.D., D.Sc.</td>
<td>Karolinska Institute Stockholm, Sweden</td>
</tr>
<tr>
<td>Alexander Knuth, M.D.</td>
<td>National Center for Cancer Care and Research, Hamad Medical Corporation Doha, Qatar</td>
</tr>
<tr>
<td>Lewis L. Lanier, Ph.D.</td>
<td>University of California, San Francisco San Francisco, CA</td>
</tr>
</tbody>
</table>
The Clinical Accelerator has a network of nearly 90 leading cancer immunologists across 12 countries, who bring unparalleled expertise to the design, planning, and execution of our clinical trials.
YOUNG PHILANTHROPISTS COUNCIL

BOARD
Priyanka Sewhani
All About the Optics
New York, NY

Catherine Borod
Partners & Spade
New York, NY

Anna-Nora Bernstein
Freelance Film Producer
New York, NY

Anna Maria Barbuti
St. Johns University
New York, NY

Samuel Obletz
Goldman Sachs
New York, NY

Anju Dhillon
Goldman Sachs
New York, NY

STAFF
Arthur N. Brodsky, Ph.D.
Science Writer

Rupinder Kaur
Senior Manager of Operations
and Officer of Planned Giving

Shana Liew
Digital Media Manager

Vanessa M. Lucey, Ph.D., MBA
Associate Director, Clinical Venture Fund and Accelerator

Qing Hua Zhang
Controller

CONSULTANT
Adam Kolom
Managing Director, Clinical Accelerator

CANCER IMMUNOTHERAPY CONSORTIUM

STEERING COMMITTEE CHAIRS
Daniel S. Chen, M.D., Ph.D.
Genentech
South San Francisco, CA

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA

MEMBERS
Cedrik M. Britten, M.D.
GlaxoSmithKline
Stevenage, United Kingdom

Roger D. Dansey, M.D.
Merck Research Laboratories
Rahway, NJ

Glenn Dranoff, M.D.
Novartis Institutes for BioMedical Research
Cambridge, MA

Robert M. Herschberg, M.D., Ph.D.
Celgene and VeriRex Pharmaceuticals
Seattle, WA

Michael Kalos, Ph.D.
Eli Lilly & Company
New York, NY

Nils Lomberg, Ph.D.
Bristol-Myers Squibb
Milpitas, CA

Israel Lowy, M.D., Ph.D.
Regeneron
Tarrytown, NY

Ira Mellman, Ph.D.
Genentech, Inc.
South San Francisco, CA

David M. Reese, M.D.
Amgen
Thousand Oaks, CA

Arvin Yang, M.D., Ph.D.
Bristol-Myers Squibb
Princeton, NJ

CANCER IMMUNOTHERAPY CONSORTIUM

STEERING COMMITTEE CHAIRS
Daniel S. Chen, M.D., Ph.D.
Genentech
South San Francisco, CA

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA

MEMBERS
Cedrik M. Britten, M.D.
GlaxoSmithKline
Stevenage, United Kingdom

Roger D. Dansey, M.D.
Merck Research Laboratories
Rahway, NJ

Glenn Dranoff, M.D.
Novartis Institutes for BioMedical Research
Cambridge, MA

Robert M. Herschberg, M.D., Ph.D.
Celgene and VeriRex Pharmaceuticals
Seattle, WA

Michael Kalos, Ph.D.
Eli Lilly & Company
New York, NY

Nils Lomberg, Ph.D.
Bristol-Myers Squibb
Milpitas, CA

Israel Lowy, M.D., Ph.D.
Regeneron
Tarrytown, NY

Ira Mellman, Ph.D.
Genentech, Inc.
South San Francisco, CA

David M. Reese, M.D.
Amgen
Thousand Oaks, CA

Arvin Yang, M.D., Ph.D.
Bristol-Myers Squibb
Princeton, NJ

CANCER IMMUNOTHERAPY CONSORTIUM

STEERING COMMITTEE CHAIRS
Daniel S. Chen, M.D., Ph.D.
Genentech
South San Francisco, CA

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA

MEMBERS
Cedrik M. Britten, M.D.
GlaxoSmithKline
Stevenage, United Kingdom

Roger D. Dansey, M.D.
Merck Research Laboratories
Rahway, NJ

Glenn Dranoff, M.D.
Novartis Institutes for BioMedical Research
Cambridge, MA

Robert M. Herschberg, M.D., Ph.D.
Celgene and VeriRex Pharmaceuticals
Seattle, WA

Michael Kalos, Ph.D.
Eli Lilly & Company
New York, NY

Nils Lomberg, Ph.D.
Bristol-Myers Squibb
Milpitas, CA

Israel Lowy, M.D., Ph.D.
Regeneron
Tarrytown, NY

Ira Mellman, Ph.D.
Genentech, Inc.
South San Francisco, CA

David M. Reese, M.D.
Amgen
Thousand Oaks, CA

Arvin Yang, M.D., Ph.D.
Bristol-Myers Squibb
Princeton, NJ

STAFF
SENIOR STAFF
Jill O’Donnell-Tormey, Ph.D.
Chief Executive Officer and Director of Scientific Affairs

Brian M. Brewer
Director of Marketing and Communications

Lynne A. Hamer
Director of Grants Administration and Special Events

Alfred R. Massidas
Chief Financial Officer and Director of Human Resources

Sharon Slade
Director of Strategic Initiatives

STAFF
Arthur N. Brodsky, Ph.D.
Science Writer

Rupinder Kaur
Senior Manager of Operations and Officer of Planned Giving

Michelle Liew
Digital Media Manager

Melinda Lopez
Receptionist/ Administrative Assistant

Vanessa M. Lucey, Ph.D., MBA
Associate Director, Clinical Venture Fund and Accelerator

Caitlin Mackaman
Manager of Individual Giving

Katherine McCluskey
Event Coordinator

CONSULTANT
Adam Kolom
Managing Director, Clinical Accelerator

Shasell Negron
General Manager / Workplace Giving Campaign Manager

Alexa Schles
Graphic Designer

Devi Sharma
Donations Processing Manager

Marla A. Sincavage
Associate Director, Corporate and Foundation Relations

Denise Upton
Manager of Grants Administration

Jasmine Wright
Events Coordinator and Assistant to the CEO

Qing Hua Zhang
Controller

CANCER IMMUNOTHERAPY CONSORTIUM

STEERING COMMITTEE CHAIRS
Daniel S. Chen, M.D., Ph.D.
Genentech
South San Francisco, CA

Axel Hoos, M.D., Ph.D.
GlaxoSmithKline
Collegeville, PA

MEMBERS
Cedrik M. Britten, M.D.
GlaxoSmithKline
Stevenage, United Kingdom

Roger D. Dansey, M.D.
Merck Research Laboratories
Rahway, NJ

Glenn Dranoff, M.D.
Novartis Institutes for BioMedical Research
Cambridge, MA

Robert M. Herschberg, M.D., Ph.D.
Celgene and VeriRex Pharmaceuticals
Seattle, WA

Michael Kalos, Ph.D.
Eli Lilly & Company
New York, NY

Nils Lomberg, Ph.D.
Bristol-Myers Squibb
Milpitas, CA

Israel Lowy, M.D., Ph.D.
Regeneron
Tarrytown, NY

Ira Mellman, Ph.D.
Genentech, Inc.
South San Francisco, CA

David M. Reese, M.D.
Amgen
Thousand Oaks, CA

Arvin Yang, M.D., Ph.D.
Bristol-Myers Squibb
Princeton, NJ

STAFF
SENIOR STAFF
Jill O’Donnell-Tormey, Ph.D.
Chief Executive Officer and Director of Scientific Affairs

Brian M. Brewer
Director of Marketing and Communications

Lynne A. Hamer
Director of Grants Administration and Special Events

Alfred R. Massidas
Chief Financial Officer and Director of Human Resources

Sharon Slade
Director of Strategic Initiatives

STAFF
Arthur N. Brodsky, Ph.D.
Science Writer

Rupinder Kaur
Senior Manager of Operations and Officer of Planned Giving

Michelle Liew
Digital Media Manager

Melinda Lopez
Receptionist/ Administrative Assistant

Vanessa M. Lucey, Ph.D., MBA
Associate Director, Clinical Venture Fund and Accelerator

Caitlin Mackaman
Manager of Individual Giving

Katherine McCluskey
Event Coordinator

CONSULTANT
Adam Kolom
Managing Director, Clinical Accelerator

Shasell Negron
General Manager / Workplace Giving Campaign Manager

Alexa Schles
Graphic Designer

Devi Sharma
Donations Processing Manager

Marla A. Sincavage
Associate Director, Corporate and Foundation Relations

Denise Upton
Manager of Grants Administration

Jasmine Wright
Events Coordinator and Assistant to the CEO

Qing Hua Zhang
Controller
Lasting Impact

The Cancer Research Institute has a long tradition of responsible stewardship of donor funds. We receive the highest marks from charity watchdog groups, including four out of four stars from Charity Navigator and an “A” grade from CharityWatch. CRI also meets all 20 standards of the Better Business Bureau Wise Giving Alliance. Donors to CRI can be confident that their donation, in any amount, will do the most good possible.

OUTRIGHT GIFTS

Cash
Donations by check or credit card may be sent directly to the Cancer Research Institute or processed through our secure website at cancerresearch.org/donate

Property Other Than Cash
Donating securities, automobiles, and similar properties can often be a tax-efficient method for making a meaningful gift to CRI. Visit cancerresearch.org/ways-to-give

Workplace Giving Programs
Ask your human resources department if your company may have a plan through which you can contribute to CRI, or contact us to learn how to set up a program at your workplace.

Matching Gifts
You can contact your human resources department to inquire if your employer matches contributions, or browse our online matching gift database to see if your company is listed at cancerresearch.org/match

Planned Gifts
Include bequests made through a living trust or inclusion of the Cancer Research Institute in your will as a beneficiary of cash, securities, or personal property. Your bequest should include the Institute’s federal tax ID number (13-1837442) and a statement such as the following:

“I bequeath to the Cancer Research Institute, a not-for-profit corporation of the State of New York, having its principal office at One Exchange Plaza, 55 Broadway, Suite 1802, New York, New York 10006, the sum of $____ for its general operating purposes.”

You should, of course, always consult your attorney and tax advisor for the formal writing of your will and to discuss the tax implications of any form of planned giving. Learn more online at legacy.cancerresearch.org.

Community Fundraising
Want to hold a bake sale to raise money for cancer research? How about a fashion show, dinner, or a music concert? Maybe you’re getting married and would prefer guests give to charity in lieu of gifts. We offer support for these and other fundraising ideas. Visit cancerresearch.org/fundraise to learn more about how you can organize your own special event and become a part of Team CRI.

FOR CORPORATE PARTNERS

No one organization, company, or group can solve the cancer problem alone. It takes collaboration to change the course of cancer. CRI actively seeks out and welcomes opportunities to work together with others to develop educational and awareness-building programs designed to advance the pace of progress in cancer immunotherapy research. Contact Sharon Slade at sslade@cancerresearch.org or (212) 688-7515 x230 to learn more.